PET and MRI Imaging of Brain Tumors Using [18F]PARPi

Memorial Sloan Kettering Cancer Center (MSK)

Status and phase: Active, not recruiting; Early Phase 1

Conditions: Brain Tumor; Brain Cancer

Treatments: Drug: [18F]PARPi; Diagnostic Test: PET/MR with [18F]PARPi

Study type: Interventional

Funder types: Other

Identifiers

NCT04173104

19-311

Details and patient eligibility

About

This study is to collect data about how 18FPARPi can be used together with PET/positron emission tomography and MRI/magnetic resonance imaging scans to take pictures of brain cancer

Enrollment: 5 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with new or suspected recurrent brain tumors (including suspected recurrent brain tumors showing growth from any preceding scan)
• Age >/= 18 years
• Minimum at least one brain lesion size >/= 1.5cm diameter
• Scheduled to undergo treatment at MSK
• Willingness to sign informed consent
• Able to receive intravenous gadolinium contrast per MSK Department of Radiology guidelines

Exclusion criteria

• Any contraindication to 3T MRI (PET/MR scanner is 4.0 Tesla)
• Pregnancy or breast-feeding women

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

Participants with Brain Cancer

Experimental group

Description:

Participants with new or suspected recurrent brain tumors

Treatment:

Diagnostic Test: PET/MR with [18F]PARPi

Drug: [18F]PARPi